Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Candidates for therapy: HBV.

Geoffrey Dusheiko1

  • 1Centre for Hepatology, Royal Free and University College School of Medicine, Pond Street, London NW3 2QG, UK. g.dusheiko@medsch.ucl.ac.uk

Journal of Hepatology
|December 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of Hepatitis B core-related antigen (HBcrAg) as a biomarker in cohorts from the United Kingdom and South Africa.

The Journal of infection·2025
Same author

Prioritising viral hepatitis elimination to prevent hepatocellular carcinoma: A public health approach for effective preventive hepatology.

JHEP reports : innovation in hepatology·2025
Same author

Hepatitis B virus resistance to nucleos(t)ide analogue therapy: WHO consultation on questions, challenges, and a roadmap for the field.

The Lancet. Microbe·2025
Same author

The surety or otherwise of leaving chronic hepatitis B untreated.

The lancet. Gastroenterology & hepatology·2024
Same author

HBV eradication from the host: Current understanding and challenges.

Clinical liver disease·2024
Same author

Peer support for people living with hepatitis B virus-A foundation for treatment expansion.

Journal of viral hepatitis·2024
Same journal

Moving Too Fast? A Meta-Analysis Calls for Caution on TNF Inhibitors as First-Line Therapy for Autoimmune Hepatitis.

Journal of hepatology·2026
Same journal

Anserine restores antibacterial immunity in cirrhosis via a protective CCL5-mediated hepatocyte-CD44<sup>+</sup>pDC crosstalk.

Journal of hepatology·2026
Same journal

Anti-CCL2-conjugated platelets attenuate early allograft and ischemia-reperfusion injury by inhibiting monocyte infiltration.

Journal of hepatology·2026
Same journal

A precision randomized trial of hepatitis C treatment support among people who inject drugs in India: The STOP-C Trial.

Journal of hepatology·2026
Same journal

Response to "Single-nucleus and spatial transcriptomic analyses reveal intra-tissue heterogeneity of PNPLA3".

Journal of hepatology·2026
Same journal

One-stop liquid biopsy: Can a single blood sample reveal the full spectrum of liver disease?

Journal of hepatology·2026
See all related articles

Hepatitis B (HBV) and HIV co-infection presents unique challenges, increasing mortality risk and complicating treatment. Managing HBV in HIV patients requires careful consideration of treatment timing and impact on both infections.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Immunology

Background:

  • Hepatitis B (HBV) can cause significant liver damage, including cirrhosis and hepatocellular carcinoma.
  • HIV and HBV co-infection is associated with poorer outcomes, such as reduced HBeAg seroconversion rates and higher HBV DNA levels.
  • Immune reconstitution in HIV patients can exacerbate HBV-related hepatitis.

Purpose of the Study:

  • To outline the complexities of Hepatitis B and HIV co-infection.
  • To discuss the impact of co-infection on disease progression and treatment strategies.
  • To highlight the importance of tailored treatment approaches for co-infected patients.

Main Methods:

  • Review of clinical presentations and outcomes in HBV/HIV co-infected patients.

Related Experiment Videos

  • Analysis of treatment considerations based on disease status (naïve, experienced, resistant HBV).
  • Evaluation of the interplay between HIV, HBV, and their respective treatments.

    • Main Results:

    • Co-infection increases the risk of mortality compared to HBV alone.
    • HIV and its treatment significantly influence the natural history of HBV.
    • Treatment aims to suppress HBV replication, reduce liver damage, and lower infectivity.

    Conclusions:

    • Management of HBV in HIV co-infected patients requires special treatment considerations.
    • Treatment decisions must account for the impact of HBV therapy on HIV and vice versa.
    • Early and appropriate management is crucial to alter outcomes in co-infected individuals.